The magnitude and coherence of these effects are comparable to those described for SGLT2 inhibitors and other insulin-sensitizing agents that simultaneously modulate glycemia, lipid profile and markers of oxidative stress, although our models are shorter in duration and less complex than chronic T2DM models [4,5,9,10,11,12,29,30,31,39]. The gene discussed is INS; the disease is type 2 diabetes mellitus.